We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Allogene Therapeutics Stock

Invest in or calculate the value of your shares in Allogene Therapeutics or other pre-IPO companies through EquityZen's platform.

Get Started

Allogene Therapeutics Stock

Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.

About Allogene Therapeutics Stock

Headquarters

South San Francisco, CA, US

Total Funding

532M

Industries

Software, Data and Analytics, Artificial Intelligence

Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Allogeneic CAR T therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. This approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for CAR T treatment.

Allogene Therapeutics Management

Leadership team at Allogene Therapeutics

Chief Executive Officer and Co-Founder

David Chang

Locked Features

Join now and verify your accreditation status to gain access to:

  • Allogene Therapeutics current valuation
  • Allogene Therapeutics stock price
  • Available deals in Allogene Therapeutics and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Allogene Therapeutics stock?

Accredited investors can buy pre-IPO stock in companies like Allogene Therapeutics through EquityZen funds. These investments are made available by existing Allogene Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Allogene Therapeutics stock?

Shareholders can sell their Allogene Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 320K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 42K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."